{"name":"ARS Pharmaceuticals, Inc.","slug":"ars-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Neffy","genericName":"Neffy","slug":"neffy","indication":"Other","status":"marketed"},{"name":"ARS-1","genericName":"ARS-1","slug":"ars-1","indication":"Phase 2 for [insert indication here, if known]","status":"phase_2"},{"name":"ARS-1 with URTI","genericName":"ARS-1 with URTI","slug":"ars-1-with-urti","indication":"Other","status":"phase_1"},{"name":"ARS-1 without URTI","genericName":"ARS-1 without URTI","slug":"ars-1-without-urti","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Neffy","genericName":"Neffy","slug":"neffy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARS-1","genericName":"ARS-1","slug":"ars-1","phase":"phase_2","mechanism":"ARS-1 is a small molecule that targets the [insert target here, if known].","indications":["Phase 2 for [insert indication here, if known]"],"catalyst":""},{"name":"ARS-1 with URTI","genericName":"ARS-1 with URTI","slug":"ars-1-with-urti","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARS-1 without URTI","genericName":"ARS-1 without URTI","slug":"ars-1-without-urti","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxNenk4MVF0UXptNmFWSWJfSm1HRkdFMkF6S0N5UFpjM2JsaWpHbkc4RExkQmtQaGU5OUtQdjJQMmlWS3djTkl2eG9WTkVMUlZybXZ2SXlXazAwTlNXZm9lQnlNTGdRNGtVUldRNU5neTZIUU1keUZiUGp5cUxmTmY1WGVVbXlhZmROVmh3SDhKNFE4YzdxUVdRdmRNVXpLRHhBcl90ck9pRDlzTW9TZ1Qxb3VyZXo0Z0JORG0zem43dmNPUFVTU2Q4RGxqZjdTWmtLcFlUNVBLYVdZWGxISTdSMzJiRno4RUhabFZnNGd5c21taG5PZkxCeGlrajhoX1JWUG44eDBydTJ4T04tajVKYUJKVDBjV2hDTWd6aG03eVJvOUNvaWJod2lMRXp5MlFISkxGY3FlM1htaXAxYlQyX29YZlFTS0s2R2plZTJVUnlCNzQ?oc=5","date":"2026-03-27","type":"pipeline","source":"MSN","summary":"ARS Pharma rises after Japan nod for neffy nasal spray for allergy - MSN","headline":"ARS Pharma rises after Japan nod for neffy nasal spray for allergy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxNTzM1Y0pZWTZ5aER5ekFmWXNjemZTUERSMXpWd0F6M2xmc0F3MnNyLWNTR2tEQjJKeTh2NzhoNjRuY3NRa09HX2hoRndtQmlraWRNa1lrNHp5Mm9EWHJ4UmhLOV9XUHVSNFNqLTlxSFI4dmxhWGtkelg1N2R5dnhHWXUxc0hxclBOa1RTVWFFbGpCSlpjMnRYNFhIZmNfcFY5b2dFNUhyUjVOenRuWDBtNkRnVEVnYmhiTkUwTWZ4azQ2ZXNKNlh3WmR0c1ByclNtUTVuNG5VRUFiUjNlR3RnT1AybDFwZmFPdGwyYlNER3JOUnltOHJvLTVQUkw4MHZNLWk5QjV2eVYyNnEybzR5d0JzWQ?oc=5","date":"2026-03-27","type":"regulatory","source":"GlobeNewswire","summary":"ARS Pharmaceuticals Receives FDA Approval to Remove Age - GlobeNewswire","headline":"ARS Pharmaceuticals Receives FDA Approval to Remove Age","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQcGlWZXJJblI0Yi1HQTRvdHp5WGpINzZSSUVwNkIxN2RKVEVZczV6N1lkNzBrM0NINFg2bWNqVWdOLWxuT3laWlRxV3NKTUZ4d04zU2RnMlhCbm1SclYtdE5jTlA0ZUFUWFFmLWdzaXdaaHZ0cGJkZVd4emxDbHNCMlJZaU9oX2VRMHN1RFRpX3dQaHVyZGxFRFlhWDRlb1RFLTl4S1RJSlFRSkNrOUxQWUw4eDhfUFp6N2RiMw?oc=5","date":"2026-03-11","type":"pipeline","source":"Seeking Alpha","summary":"ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY) - Seeking Alpha","headline":"ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQTkIwSFJ2S1JqTGdPZmoxaFNZbEJINmt5WEpYY1JXMnF0cHh2MkNLS0N6WGxjUDBqX0szQ2oxeWtJUktFR0lZTUhyRkIxRmRUdXpWWkdNOWg4amh5UzVzcFBsVEg0WjFkSjNId0dUbjl2cnc5V3hEZFBEVDItNlhkMFcta3l1dF9Eb09JZ3pDSWRKclAzNDl2cndmZnJWY2dQSDN4NFZwNmYzSTlkM2dfdUpR?oc=5","date":"2026-03-09","type":"pipeline","source":"Stock Titan","summary":"ARS Pharmaceuticals (Nasdaq: SPRY) grows neffy sales to $72M but posts $171M 2025 loss - Stock Titan","headline":"ARS Pharmaceuticals (Nasdaq: SPRY) grows neffy sales to $72M but posts $171M 2025 loss","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQWHFaOGhzWGpHNUZuUUotYXZzSEoxRUNobko5ZlIwUFdNeEJDLVpWZ294emV6OVRiTlBIcktQUWNpT3hWOEhuRTg0Z3VvXzFWNzQ0d0RUTGUtY2tKYlZFSEZkZDhYRzNvYzFWSkhkMkVteEhkNzNoTTkxS2ZlRU9rUVhKemJWdnRGNUZYenMtV2RwQQ?oc=5","date":"2026-03-09","type":"earnings","source":"Yahoo Finance","summary":"ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization - Yahoo Finance","headline":"ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNNU9QVlp2Q3ZvQzFuN0JlbWRPM2tTYmtBcDM5U3UwYmRHSUhaYXh4a2lMbFAzY3ZhRzUzUjFLeDVjZnZETlRiZ1RLRGZoUnd2eURheXl4QnFvbFhPZFV1dEE1YWh6M1FwTURzT0pSLUxPcEhBRFE2U2JGRDcxZWF1YlpZYXgtYkxDLWtzU29ud01sTGdHX1E?oc=5","date":"2026-02-23","type":"earnings","source":"Yahoo Finance","summary":"ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences - Yahoo Finance","headline":"ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results an","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPeEJMb3ZBc1dramp1NVBDRE9wNlZ3LVdhUERGNkx0R09Ja3BFcmJDZW1pWG0tWml2Tko1LW5ZdjlOU2h1RmJ6cERrLUNHeFYxeUxtNzNJdDRoRXJnczhSdGVPRWNab0lEUFRQbWtlb29YRkNIMzNyVjdqZEc1ZjdrYXgwcTRfUmpfdjZyM3pTSzVlMEduSEJkRW9rWkoyOTF2ZXEtcldOXzFqNDBWTy1yeVZOZUwxamI3N0tGNA?oc=5","date":"2026-02-23","type":"pipeline","source":"Stock Titan","summary":"Upcoming ARS Pharma call on 2025 results plus March investor conferences - Stock Titan","headline":"Upcoming ARS Pharma call on 2025 results plus March investor conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOc0hDT3lyZ2ZLcTczUEFNX09qMmxrU2xlWDBkS3A3THp4TkluSkRlbkEwN3BCMUhScVdNUkhSTWdPYUlNUXFUcTIxRFg5ZHUtOTVPaG1ZY0toWnpuWnlsQVJoc0NWT1ZyeWx4YUQ1STB5cXJzamVOMmR4cWFjTk05WXFiUTl0STlvTUU5V3Rxei1KbjgtaVl6YmszWEZlcG1aYjUxRS1KRFVhaWNfR3BOSk92X0dSYkJBNDdr?oc=5","date":"2026-02-10","type":"pipeline","source":"Stock Titan","summary":"Needle-free epinephrine nasal spray may cut costs and boost patient preference - Stock Titan","headline":"Needle-free epinephrine nasal spray may cut costs and boost patient preference","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-02","type":"pipeline","source":"GlobeNewswire","summary":"EURneffy® 1 mg (adrenaline nasal spray) Recommended for - GlobeNewswire","headline":"EURneffy® 1 mg (adrenaline nasal spray) Recommended for","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5ubV9TclZaQ2JWOHVPMjZvdGM0T2JuRmsyRG5tRDRJRWVnTDFnOFlfZkVDb2VzM3IydjJyc0xfb19Nc0lEbXNzakpsMHduaGl1eUpfdDhpN2ZiaGNFQ1ZZVUJLTlFpbjluUnhYeVJGQk1nZmZYV2tocmZ0MFRXQQ?oc=5","date":"2026-01-09","type":"regulatory","source":"Yahoo Finance","summary":"ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating - Yahoo Finance","headline":"ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOdEw4R1BaMWhUYnlUSUV1RXdhRG1yLWZCRUFqb0NHWkZ2WG84NHotSEktMDl4blU1Z2w2amJiVHpkelNCU2JJcThCSnVCaDBFQ1g4QS1nRlJUZ1ZTTFNKTl9MSW9kbHFFTzdhX0dhbTVSUGlGUndobGVpRldGQ1JNdVY5eC1vR25QMHJRNDYtYnZsbEVlREsxeDlQOXE2QjFkMHNQb0xUSVNNRWx2cDZ5V2xxOGo5dE5MN0RDNjhJemdSNEhvMzZR?oc=5","date":"2025-10-08","type":"patent","source":"Wilson Sonsini","summary":"Firm Advises ARS Pharma on Patent Matters Related to Loan Facility Up to $250 Million - Wilson Sonsini","headline":"Firm Advises ARS Pharma on Patent Matters Related to Loan Facility Up to $250 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxObjMxZkxidmdjR0kwT21pTHFxQVMtemg2eXU0V0hhR1N1OEgwNjFWMkxKTG9RZFVueWluNVBOOXlnWkNoWU56dDktRF9pRC1zWGoxckgycy1QQlhJRDdGUkxoSlNrY2VEcDByNWNfY0UzblBwNUdVZWZlR25xSjJOaG9xUUVuN3hLam13Q1RzSDRITFFUeWpWQWQ2RVBJMmQ3Y1NMSzRzZWxJUkZPMzBtUF9ZSGY1SF9wWW9iWGlYRXk0cG9zSlQyNnBvN3ZWZ3RydFE1ZFVsWjljRFJqYjBQcjgycjA1ZjRLdlI5OW9nUzB6RER2WkkzWlhsZDFGNkwtNGhUUUotdTZOMWh2azBEMWhEalhwaVRhaDlaT3ZpUEdIOF9TMEMzVDRoSkE?oc=5","date":"2025-09-30","type":"pipeline","source":"prnewswire.com","summary":"RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies - prnewswire.com","headline":"RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for In","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":1,"phase_2":1,"phase_1":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}